Influenza A Virus A/hong Kong/2671/2019 Ivr-208 (h3n2) Antigen (formaldehyde Inactivated)

For adults aged 18 to 64, the standard dose of a vaccine containing the A/Hong Kong/2671/2019 (H3N2) antigen is typically 0.5 mL, administered as a single intramuscular (IM) injection. This dose usually contains 15 micrograms (mcg) of the hemagglutinin (HA) protein for this specific strain.

For adults aged 65 and older, a 'High-Dose' version may be administered. This formulation typically contains 60 mcg of the HA protein per strain (a four-fold increase) in a 0.7 mL or 0.5 mL dose, depending on the specific manufacturer (e.g., Fluzone High-Dose). The higher antigen load is designed to elicit a more robust immune response in the elderly population.

Pediatric dosing is strictly age-dependent and follows CDC/ACIP (Advisory Committee on Immunization Practices) guidelines:

• Children 6 months through 35 months: The dose may be 0.25 mL or 0.5 mL depending on the specific vaccine brand (e.g., Fluarix vs. Fluzone).
• Children 3 years through 17 years: The standard dose is 0.5 mL IM.
• Priming Dose: Children aged 6 months through 8 years who have not previously received at least two doses of influenza vaccine (at any time) require two doses administered at least 4 weeks apart. This antigen would be a component of both doses.

Renal Impairment

No dosage adjustment is required for patients with renal impairment or those on dialysis. The antigen is not cleared renally, and its safety profile remains unchanged in this population.

Hepatic Impairment

No dosage adjustment is required for patients with hepatic impairment. There is no evidence that liver dysfunction affects the processing of inactivated viral antigens.

Elderly Patients

As noted, elderly patients often receive a higher concentration of the antigen (High-Dose) or an adjuvanted version (e.g., Fluad) to ensure adequate seroconversion (the development of protective antibody levels).

This agent is administered exclusively by a healthcare professional. It is given via intramuscular injection, typically in the deltoid muscle of the upper arm for adults and older children. For infants and small children, the anterolateral aspect of the thigh is the preferred site.

• Preparation: The vaccine should be shaken well before administration to ensure a uniform suspension. It should be inspected for particulate matter or discoloration.
• Food/Drink: There are no restrictions regarding food or drink before or after receiving this antigen.
• Storage: Vaccines containing this antigen must be stored under refrigeration (2°C to 8°C or 36°F to 46°F). They must never be frozen.

Since influenza vaccination is typically an annual single-dose event, a 'missed dose' refers to failing to get vaccinated during the flu season. If a child requires two doses and misses the second, it should be administered as soon as possible, provided the flu season is still ongoing.

An overdose of an inactivated antigen is highly unlikely as it is administered in pre-measured single-dose syringes. However, an accidental double dose would likely only increase the risk of local injection site reactions (swelling, pain) and transient systemic symptoms (fever). There is no specific 'antidote'; management is supportive (e.g., acetaminophen for fever).

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

The most frequently reported side effects associated with the Influenza A/Hong Kong/2671/2019 (H3N2) antigen are localized to the site of administration. These are typically mild and resolve within 24 to 48 hours.

• Injection Site Pain: A dull ache or soreness in the deltoid muscle, often described as feeling like a 'bruise.'
• Erythema (Redness): A small red patch at the needle entry point.
• Induration (Swelling): A slight firmness or puffiness at the injection site.
• Fatigue: A general feeling of tiredness or lethargy as the immune system begins its response.
• Headache: Mild to moderate tension-type headache.

These systemic reactions are more common in children and 'vaccine-naive' individuals:

• Myalgia (Muscle Aches): Generalized body aches, similar to the early stages of a cold.
• Arthralgia (Joint Pain): Mild stiffness in the joints.
• Low-grade Fever: Temperature typically between 99.5°F and 101°F.
• Chills: Transient shivering or feeling cold.
• Nausea: Mild upset stomach, usually short-lived.

• Lymphadenopathy: Swelling of the lymph nodes, usually in the axilla (armpit) on the side of the injection.
• Urticaria (Hives): A localized or generalized itchy rash.
• Syncope (Fainting): Often a vasovagal response to the needle rather than the antigen itself, primarily seen in adolescents.

> Warning: Stop taking Influenza A Virus A/hong Kong/2671/2019 Ivr-208 (h3n2) Antigen (formaldehyde Inactivated) and call your doctor immediately if you experience any of these.

• Anaphylaxis: A severe, life-threatening allergic reaction characterized by difficulty breathing, swelling of the tongue or throat, rapid heartbeat, and a sharp drop in blood pressure.
• Guillain-Barré Syndrome (GBS): A rare neurological disorder where the body's immune system attacks the nerves. Symptoms include weakness or tingling sensations, usually starting in the legs and spreading to the upper body. The risk is estimated at 1-2 additional cases per million people vaccinated.
• Shoulder Injury Related to Vaccine Administration (SIRVA): Severe pain and loss of range of motion in the shoulder, caused by incorrect needle placement into the bursa or joint space.
• Facial Palsy (Bell's Palsy): Temporary weakness or paralysis of the muscles on one side of the face (extremely rare and causality is often debated).

There are no known long-term side effects associated with the inactivated A/Hong Kong/2671/2019 (H3N2) antigen. The antigen itself is cleared from the body within days. The only long-term 'effect' is the persistence of memory B-cells and T-cells that provide protection for the duration of the flu season.

No FDA black box warnings exist for Influenza A Virus A/hong Kong/2671/2019 Ivr-208 (h3n2) Antigen (formaldehyde Inactivated). It is generally considered safe for the vast majority of the population, including those with chronic medical conditions.

Report any unusual symptoms to your healthcare provider. You may also report side effects to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967.

Before receiving a vaccine containing the Influenza A Virus A/Hong Kong/2671/2019 (H3N2) antigen, patients must be screened for a history of hypersensitivity to any component of the vaccine. This includes not just the viral antigen, but also residual 'process' ingredients such as egg proteins (ovalbumin), formaldehyde (used for inactivation), or antibiotics (like neomycin or polymyxin B) used during manufacturing to prevent bacterial contamination.

No FDA black box warnings for Influenza A Virus A/hong Kong/2671/2019 Ivr-208 (h3n2) Antigen (formaldehyde Inactivated).

• Allergic Reactions / Anaphylaxis Risk: While rare, severe allergic reactions can occur. Clinics must be equipped with epinephrine and medical personnel trained to manage anaphylaxis.
• Guillain-Barré Syndrome (GBS): If GBS has occurred within 6 weeks of a previous influenza vaccination, the decision to give this antigen should be based on a careful evaluation of the potential benefits and risks.
• Febrile Seizures: In young children, there is a very small increased risk of febrile seizures when influenza vaccines are co-administered with certain other vaccines (like PCV13). This is generally not a contraindication but a point for monitoring.
• Altered Immunocompetence: Individuals with weakened immune systems (due to HIV, cancer, or immunosuppressive drugs) may have a reduced immune response to the antigen. It is not a safety risk (as the virus is dead), but the vaccine may be less effective.

There are no routine lab tests (like blood counts or liver panels) required after receiving this antigen. However, patients should be observed for at least 15 minutes following the injection to monitor for immediate allergic reactions or syncope (fainting).

This antigen has no known effect on the ability to drive or operate heavy machinery. If a patient experiences transient dizziness or fatigue, they should wait until these symptoms resolve before driving.

There is no direct contraindication for alcohol use. However, excessive alcohol consumption can theoretically suppress the immune response and may exacerbate side effects like headache or fatigue.

As this is a single-dose prophylactic agent, 'discontinuation' does not apply in the traditional sense. Once the antigen is injected, the process cannot be reversed. Future annual doses may be declined, but this leaves the individual susceptible to future circulating flu strains.

> Important: Discuss all your medical conditions with your healthcare provider before starting Influenza A Virus A/hong Kong/2671/2019 Ivr-208 (h3n2) Antigen (formaldehyde Inactivated).

There are no absolute drug-drug contraindications that would result in a fatal or severe chemical reaction. However, certain combinations are avoided for efficacy reasons:

• Live Attenuated Influenza Vaccine (LAIV): You should not receive the inactivated A/Hong Kong/2671/2019 antigen and a live flu nasal spray at the same time, as they are redundant and increase the risk of side effects without added benefit.

• Immunosuppressive Therapies: Drugs such as high-dose corticosteroids (e.g., prednisone >20mg/day), chemotherapy, or biologics (e.g., rituximab, TNF-inhibitors) can significantly blunt the immune system's ability to respond to the antigen. This results in 'vaccine failure,' where the person is vaccinated but does not develop protective antibodies.
• Anticoagulants: Patients on warfarin (Coumadin), apixaban (Eliquis), or other blood thinners are at an increased risk of hematoma (deep bruising) at the injection site. A fine-gauge needle should be used, and firm pressure applied for at least 2 minutes.

• Statins: Some studies suggest that chronic statin use might slightly reduce the antibody response to H3N2 antigens, though the clinical significance is minor, and patients are still encouraged to get vaccinated.
• Acetaminophen/NSAIDs: Routine 'pre-medication' with Tylenol or Advil before the shot is sometimes discouraged as it might theoretically dampen the initial inflammatory response needed for immunity, though taking them after the shot for side effects is perfectly acceptable.

• Egg Protein: For egg-based formulations of the A/Hong Kong/2671/2019 antigen, individuals with severe egg allergies (anaphylaxis) should ideally receive a cell-derived or recombinant version of the vaccine. If only egg-based is available, it should be administered in a medical setting capable of managing severe allergic reactions.

There are no documented interactions with St. John's Wort, ginkgo, or other common herbs. Some patients take Elderberry or Vitamin C to 'boost' the immune system, but there is no clinical evidence that these alter the efficacy of the H3N2 antigen.

• Influenza Diagnostic Tests: Because the antigen is inactivated and administered intramuscularly, it will not cause a false positive on a rapid influenza diagnostic test (RIDT) or PCR test (nasal swab).
• HIV/HCV/HTLV-1 Testing: Rarely, influenza vaccination has been associated with transient false-positive results in certain enzyme immunoassays (EIA) for HIV-1, Hepatitis C, and HTLV-1. A more specific confirmatory test (like a Western Blot or PCR) will show the result is negative.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Severe Allergic Reaction (Anaphylaxis): Anyone who has had a documented life-threatening reaction to a previous dose of any influenza vaccine or to any specific component of the vaccine containing the A/Hong Kong/2671/2019 antigen (e.g., formaldehyde, egg protein, neomycin).
• Severe Egg Allergy (Specific to Egg-Based Products): While the CDC has relaxed these guidelines, some international protocols still list severe egg allergy as an absolute contraindication for egg-grown antigens if cell-based alternatives are unavailable.

• Moderate to Severe Acute Illness: Patients with a high fever or significant illness should generally wait until they recover before receiving the antigen. This is to avoid diagnostic confusion between the symptoms of the illness and the potential side effects of the vaccine.
• History of Guillain-Barré Syndrome (GBS): If GBS occurred within 6 weeks of a previous flu shot, the patient is generally advised to avoid future flu vaccines unless the risk of severe flu complications is very high.

• Formaldehyde Sensitivity: Individuals with a contact dermatitis allergy to formaldehyde may experience a localized skin reaction, though systemic reactions are rare as the amount of residual formaldehyde is minimal (less than 0.1 mg).
• Antibiotic Sensitivity: Those allergic to neomycin or polymyxin should check the specific manufacturer's package insert, as these are often used in the viral growth medium.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Influenza A Virus A/hong Kong/2671/2019 Ivr-208 (h3n2) Antigen (formaldehyde Inactivated).

FDA Pregnancy Category: B/C (Variable by manufacturer).

Extensive clinical data and observational studies have shown that inactivated influenza antigens, including the A/Hong Kong/2671/2019 (H3N2) strain, are safe to administer during any trimester of pregnancy. In fact, vaccination is strongly recommended because pregnant women are at a significantly higher risk for severe complications from H3N2 influenza, including pneumonia and preterm labor. Furthermore, antibodies produced by the mother cross the placenta and provide 'passive immunity' to the newborn for the first several months of life.

Inactivated viral antigens do not pass into breast milk. Breastfeeding is not a contraindication, and vaccinated mothers can safely continue nursing. The protective antibodies (IgA) produced by the mother may even be passed through the milk, offering additional protection to the infant.

This antigen is approved for use in children as young as 6 months. It is not approved for infants under 6 months of age, as their immune systems do not respond reliably to the antigen and they are protected primarily by maternal antibodies. In children, the H3N2 component is crucial as this strain often causes more severe illness in the pediatric population compared to Influenza B.

Patients over 65 are a priority group for this antigen. Due to immunosenescence, the standard 15 mcg dose may be less effective. Consequently, the 'High-Dose' (60 mcg) or adjuvanted formulations are preferred. There is no increased risk of serious adverse events in the elderly, though local injection site soreness may be slightly more pronounced with high-dose versions.

As the antigen is not cleared by the kidneys, no dose adjustment is necessary. It is highly recommended for patients with chronic kidney disease (CKD) as they are considered 'high risk' for flu complications.

No adjustments are needed for patients with cirrhosis or other liver diseases. The processing of the antigen occurs in the lymphoid tissue, not the liver.

> Important: Special populations require individualized medical assessment.

Influenza A Virus A/Hong Kong/2671/2019 IVR-208 (H3N2) Antigen acts as an immunogen. The primary target is the B-lymphocyte receptor. Upon recognition of the hemagglutinin (HA) protein, B-cells undergo clonal expansion. The HA protein is the 'key' the virus uses to enter cells; by creating antibodies that block this 'key,' the vaccine prevents the viral 'lock' (sialic acid receptors on human respiratory cells) from being engaged.

• Onset of Effect: Antibody levels typically begin to rise within 7 days, reaching protective titers (seroconversion) by 14 to 21 days post-injection.
• Duration: Protective antibody levels generally persist for 6 to 12 months, which is why annual revaccination is required as titers wane and the virus undergoes 'antigenic drift.'
• Tolerance: There is no pharmacological tolerance; however, 'original antigenic sin' is a phenomenon where the body's first exposure to a flu strain shapes all future immune responses to similar strains.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Intramuscular) |

| Protein Binding | N/A |

| Half-life (Antigen) | ~24-48 hours (local) |

| Tmax (Antibody) | 2-3 weeks |

| Metabolism | Proteolytic degradation |

| Excretion | Cellular debris removal |

The antigen consists of purified viral proteins. The molecular weight of the hemagglutinin trimer is approximately 220 kDa. It is soluble in phosphate-buffered saline (PBS) and is stabilized in a clear to slightly opalescent suspension.

Classified as a Standardized Chemical Allergen [EPC] and a Vaccine Antigen. It belongs to the broader class of Inactivated Viral Vaccines. Related medications include other H1N1 antigens (like A/Victoria/2570/2019) and Influenza B antigens (Washington or Phuket lineages).